Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Danaflex-Lab ApS
APS
Active
CVR 43725157
Gefionsvej 20
Wholesale of pharmaceutical and medical goods · NACE 4646
Est. 2022
1 employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2024
DKK 323K
-412% vs 2023
EBITDA margin
100.0%
+412% vs 2023
Equity ratio
20.5%
Financial strength
Net profit 2024
DKK 247K
+383% vs 2023
EBITDA — year on year
DKK millions
0M
0M
1M
1M
1M
0M
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
DKK 323K
-412%
EBITDA
DKK 323K
+412%
Net profit
DKK 247K
+383%
Total assets
DKK 978K
+34%
Equity
DKK 200K
+523%
Employees
1
—
Company information
Legal name
Danaflex-Lab ApS
CVR number
43725157
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
20. december 2022
Share capital
DKK 40.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabet formål er at drive handel med laboratorieudstyr og andre produkter, primært til hospitaler og høreklinikker, og dermed beslægtet virksomhed.
Contact
Address
Gefionsvej 20
Phone
+4545814004
Email
ks@danaflex.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Wholesale of pharmaceutical and medical goods
Companies in Hillerød
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
EBITDA
DKK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
Income statement
DKK thousands
Item
2023
2024
Revenue
-103
323
Staff expenses
-0
-0
EBITDA
-103
323
Depreciation & amort.
-0
-0
EBIT
-103
323
Net financials
-8
-5
Profit before tax
-112
317
Tax
-25
70
Net profit
-87
247
Balance sheet
DKK thousands
Item
2023
2024
Total assets
731
978
Equity
-47
200
Long-term debt
0
0
Short-term debt
778
778
Total debt
778
778
Financial ratios
5-year trend
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
2023
2024
Equity ratio
20.5%
This company
38.2%
Market median
-46% vs market
2023
2024
Return on equity
123.7%
This company
18.4%
Market median
+572% vs market
2023
2024
Net profit margin
76.7%
This company
8.1%
Market median
+847% vs market
2023
2024
Asset turnover
0.33×
This company
1.12×
Market median
-71% vs market
2023
2024
Debt / equity
3.89×
This company
0.62×
Market median
-527% vs market
2023
2024
Annual reports & filings
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2022-12-20 – 2023-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Age
Other directorships
KS
Kristian Skov Alanin
Management
Management
2022
—
—
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
ALANIN HOLDING ApS
Company
100.0%
100.0%
2022
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
ALANIN HOLDING ApS
Danaflex-Lab ApS
(this company)
Board network connections
Board members of Danaflex-Lab ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Kristian Skov Alanin
Management
0 companies